Borderline Mucinous Ovarian Tumour Producing hCG as a Paraneoplastic Tumour Marker

This case highlights an intriguing example of paraneoplastic syndrome associated with borderline ovarian tumors (BOTs), specifically in relation to elevated β-hCG levels. In typical presentations, β-hCG is primarily linked to pregnancy, but in this instance, its elevation in a non-pregnant patient underscores the complex interplay between tumors and hormonal production. The negative pelvic ultrasound and β-hCG heterophilic antibody testing effectively ruled out common causes of elevated β-hCG, such as pregnancy and phantom hCG. This strengthens the hypothesis that the raised β-hCG levels were indeed related to the tumor itself rather than external factors. The correlation between the decline in β-hCG and the patient’s response to treatment further supports the notion of a paraneoplastic phenomenon. This illustrates how certain tumors can produce hormones or hormone-like substances, leading to clinical symptoms or laboratory abnormalities that may precede the diagnosis of the primary malignancy. In this case, the production of β-hCG by the tumor exemplifies the diverse mechanisms through which neoplasms can influence the body, emphasizing the importance of a thorough investigation in patients with unusual laboratory findings. Overall, this case adds to the understanding of the clinical implications of paraneoplastic syndromes and highlights the need for clinicians to consider these syndromes when faced with atypical lab results in the context of malignancy.